CHICAGO, April 04, 2017 -- Tempus, a technology company that enables physicians to deliver personalized cancer care, has hired Erik Phelps to serve as Executive Vice President and General Counsel. Phelps will be responsible for a broad range of legal areas for the company, including general corporate matters and strategy. Prior to joining Tempus, Phelps served as General Counsel at Epic, a software company that provides electronic health records for medical groups, hospitals and healthcare organizations. Before that, he served as a partner at Michael Best & Friedrich LLP in Madison, WI where he focused on software licensing and technology related work, including with early-stage companies. He earned his bachelor’s degree from Beloit College and his J.D. from George Washington University Law School.
“Erik spent nearly a decade driving and supporting the growth of one of the largest healthcare technology providers in the world,” said Eric Lefkofsky, Co-founder and CEO at Tempus. “As Tempus continues to scale and partner with large hospital systems and academic centers, we felt it was important to bring on a seasoned leader with strategy and operations experience to accelerate our work to make personalized treatment a reality for patients diagnosed with cancer.”
“Tempus has established itself in short order as an innovator with the potential to transform the industry,” said Phelps, General Counsel at Tempus. “The opportunity to join this data-driven healthcare leader was something that I couldn’t pass up.”
Tempus has recruited a world-class team of accomplished geneticists, computational biologists, data scientists and software engineers who have developed the software and analytic tools that form the foundation of an operating system to battle cancer. The company provides molecular sequencing and clinical analysis for top academic centers, hospital systems, associations, and healthcare providers such as Mayo Clinic, University of Pennsylvania’s Abramson Cancer Center, Northwestern’s Lurie Cancer Center, and the University of Michigan Comprehensive Cancer Center.
About Tempus:
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs). For more information on Eric Lefkofsky, visit lefkofsky.com.
Contact: Tempus Clo Ewing Director of Communications [email protected]


Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions
BlueScope Steel Announces A$1 Special Dividend After Asset Sales
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 



